Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mescaline
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : MBX Capital
Deal Size : $12.0 million
Deal Type : Series A Financing
Details : The funding will be used to accelerate the development of Journey Colab’s portfolio of psychedelic compounds. Journey Colab’s lead compound, Mescaline HCl (JOUR-001), is being developed for the treatment of Alcohol Use Disorder (AUD).
Brand Name : JOUR-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 07, 2021
Lead Product(s) : Mescaline
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : MBX Capital
Deal Size : $12.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?